Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies

Leon Kircik, Joseph Fowler, Jonathan Weiss, Xiangyi Meng, Adriana Guana, Judit Nyirady, Leon Kircik, Joseph Fowler, Jonathan Weiss, Xiangyi Meng, Adriana Guana, Judit Nyirady

Abstract

Introduction: Psoriasis affecting the head and neck can be difficult to treat, and the presence of extensive and highly visible lesions may result in substantial psychosocial burdens. Secukinumab, a monoclonal antibody that selectively targets interleukin-17A, provides rapid and sustained clearance of moderate-to-severe psoriasis. The objective of this study was to evaluate the efficacy of secukinumab on moderate-to-severe psoriasis affecting the head and neck. The safety and overall efficacy of secukinumab in patients with moderate-to-severe psoriasis will be described.

Methods: Data were pooled from four phase 3 studies. To be included in the head and neck analysis, patients were required to have Baseline head and neck Psoriasis Severity Area Index (PASI) scores ≥12 and psoriasis covering ≥10% of the head and neck. Secukinumab (300 or 150 mg) was administered at Baseline, Weeks 1, 2 and 3, and then every 4 weeks from Week 4 to 48.

Results: Secukinumab demonstrated high efficacy on the head and neck and the whole body. At Week 52, head and neck PASI 90/100 subscore responses were achieved by 76.0%/68.7% of patients receiving secukinumab 300 mg, respectively, and by 61.4%/53.1% of patients receiving secukinumab 150 mg, respectively. At Week 52, whole body composite PASI 90/100 responses were achieved by 68.1%/40.8% of patients receiving secukinumab 300 mg, respectively, and by 47.6%/24.3% of patients receiving secukinumab 150 mg, respectively. Secukinumab also improved Dermatology Life Quality Index scores.

Conclusion: Secukinumab provided robust and sustained efficacy for head and neck, and whole body psoriasis, over 52 weeks, with a favorable safety profile.

Funding: Novartis Pharmaceuticals Corporation.

Trial registration: ClinicalTrials.gov identifiers, NCT01365455, NCT01358578, NCT01555125, and NCT01636687.

Keywords: Head and neck psoriasis; Moderate-to-severe psoriasis; Phase 3; Plaque psoriasis; Pooled analysis; Secukinumab.

Figures

Fig. 1
Fig. 1
Efficacy of secukinumab on the head and neck over time. Missing values were imputed by multiple imputation. Clinical response rates for a HNPASI 75, b HNPASI 90, and c HNPASI 100 from Baseline to Week 52. n represents the number of evaluable subjects. HNPASI 75/90/100, 75%/90%/100% improvement from Baseline head and neck psoriasis area and severity index scores
Fig. 2
Fig. 2
Percent change in mean HNPASI score over time. A repeated-measure, mixed-effects model was used to analyze the mean percent change from Baseline in PASI score. The median time to a 50% reduction in mean HNPASI score was estimated from parametric bootstrap samples with the use of linear interpolation between time points. CI confidence interval, HNPASI head and neck psoriasis area severity index
Fig. 3
Fig. 3
Efficacy of secukinumab on the whole body over time. Missing values were imputed by multiple imputation. Clinical response rates for a PASI 75, b PASI 90, and c PASI 100 from Baseline to Week 52. PASI 75/90/100, 75%/90%/100% improvement from Baseline psoriasis area and severity index scores

References

    1. Papp K, Berth-Jones J, Kragballe K, Wozel G, de la Brassinne M. Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereol. 2007;21:1151–1160. doi: 10.1111/j.1468-3083.2007.02424.x.
    1. Crowley J. Scalp psoriasis: an overview of the disease and available therapies. J Drugs Dermatol. 2010;9:912–918.
    1. Kragballe K. Management of difficult to treat locations of psoriasis. scalp, face, flexures, palm/soles and nails. Curr Probl Dermatol. 2009;38:160–171. doi: 10.1159/000232309.
    1. van de Kerkhof PC, Murphy GM, Austad J, Ljungberg A, Cambazard F, Duvold LB. Psoriasis of the face and flexures. J Dermatolog Treat. 2007;18:351–360. doi: 10.1080/09546630701341949.
    1. Mattei PL, Corey KC, Kimball AB. Cumulative life course impairment: evidence for psoriasis. Curr Probl Dermatol. 2013;44:82–90. doi: 10.1159/000350008.
    1. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6:383–392. doi: 10.2165/00128071-200506060-00005.
    1. Raho G, Koleva DM, Garattini L, Naldi L. The burden of moderate to severe psoriasis: an overview. Pharmacoeconomics. 2012;30:1005–1013. doi: 10.2165/11591580-000000000-00000.
    1. Young M. The psychological and social burdens of psoriasis. Dermatol Nurs. 2005;17:15–19.
    1. Young Park J, Hyun Rim J, Beom Choe Y, Il Youn J. Facial psoriasis: comparison of patients with and without facial involvement. J Am Acad Dermatol. 2004;50:582–4.
    1. Canpolat F, Cemil BC, Eskioglu F, Akis HK. Is facial involvement a sign of severe psoriasis? Eur J Dermatol. 2008;18:169–171.
    1. Chen SC, Yeung J, Chren MM. Scalpdex: a quality-of-life instrument for scalp dermatitis. Arch Dermatol. 2002;138:803–807.
    1. Sampogna F, Linder D, Piaserico S, Altomare G, Bortune M, Calzavara-Pinton P, et al. Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex. Acta Derm Venereol. 2014;94:411–414. doi: 10.2340/00015555-1731.
    1. Zampieron A, Buja A, Fusco M, Linder D, Bortune M, Piaserico S, et al. Quality of life in patients with scalp psoriasis. G Ital Dermatol Venereol. 2015;150:309–316.
    1. Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71:141–150. doi: 10.1016/j.jaad.2013.12.036.
    1. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371:326–338. doi: 10.1056/NEJMoa1314258.
    1. Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, et al. Secukinumab administration by pre-filled syringe: efficacy, safety, and usability results from a randomized controlled trial in psoriasis (FEATURE) Br J Dermatol. 2015;172:484–493. doi: 10.1111/bjd.13348.
    1. Paul C, Lacour JP, Tedremets L, Kreutzer K, Jazayeri S, Adams S, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE) J Eur Acad Dermatol Venereol. 2015;29:1082–1090. doi: 10.1111/jdv.12751.
    1. Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400–409. doi: 10.1016/j.jaad.2015.05.013.
    1. Menter A, Cather JC, Jarratt M, Meng X, Guana A, Nyirady J. Efficacy of secukinumab on moderate-to-severe plaque psoriasis affecting different body regions: a pooled analysis of four phase 3 studies. Dermatol Ther (Heidelb). 2016. doi:10.1007/s13555-016-0140-7. (Online first).
    1. Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator’s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatol Treat. 2015;26:23–31. doi: 10.3109/09546634.2013.865009.
    1. Finlay AY, Khan GK. Dermatology life quality index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x.
    1. Langley RG, Reich K, Papavassilis C, Fox T, Gong Y, Güttner A. Multiple imputation methodology is reflective of secukinumab efficacy in real clinical practice: data from the FIXTURE and ERASURE studies in moderate-to-severe plaque psoriasis (abstract). Br J Dermatol. 2014;171:e165 (Abstract P199).
    1. Katugampola RP, Lewis VJ, Finlay AY. The dermatology life quality index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol. 2007;156:945–950. doi: 10.1111/j.1365-2133.2007.07817.x.
    1. Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, et al. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial. J Drugs Dermatol. 2013;12:874–880.
    1. Griffiths CE, Sterry W, Brock F, Dilleen M, Stefanidis D, Germain JM, et al. Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept. Br J Dermatol. 2015;172:230–238. doi: 10.1111/bjd.13139.
    1. Navarini AA, Poulin Y, Menter A, Gu Y, Teixeira HD. Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2014;13:554–562.
    1. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137–174. doi: 10.1016/j.jaad.2010.11.055.
    1. Efficacy and safety of subcutaneous secukinumab in adults with moderate to severe scalp psoriasis (SCALP): . Available from . Accessed 14 Jan 2016.
    1. Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, et al. Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. Int J Dermatol. 2016;55:401–407. doi: 10.1111/ijd.13236.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する